Stoxline.com
android_stock_chart
Stock Chart

Stoxline Lite

Stoxline Pro

Option Calculator
Stoxline
Mobile

Home | Charts | Showcases | Stock Ranks | Options | ETFs | Educations

 
Tweet this page
Share on Facebook
Share on Google+

7 Binary Options

 

Enter Stock Symbol:  

Dicerna Pharmaceutic (DRNA)

13.93 0.18 (1.31%)

05-21 16:00

Open:

13.9

Pre. Close:

13.75

High:

14.18

Low:

13.69

Volume:

261,618

Market Cap:

736M

Stock Price Prediction (Update at 5:00pm est.)

If tomorrow:

Open lower

Open higher

High:

14.2 - 14.28

14.28 - 14.353

Low:

13.482 - 13.585

13.585 - 13.679

Close:

13.78 - 13.93

13.93 - 14.067

Technical analysis  (as of: 2018-05-21 4:28:25 PM)

Overall:

      

Stoxline posted a NEUTRAL today, upgraded from lower rating. This stock seems to stay at current move trend, but it could change at anytime. So it is not a good time to buy or sell, stay at where you are until next BUY or SELL signal.

Target:

Six months: 18.45     One year: 21.55

Support:

Support1: 12.10    Support2: 9.81

Resistance:

Resistance1: 15.80    Resistance2: 18.45

Pivot:

13.97

Moving Averages:

MA(5): 13.68     MA(20): 13.46

MA(100): 11.19     MA(250): 7.47

MACD:

MACD(12,26): 0.65     Signal(12,26,9): 0.74

%K %D:

%K(14,3): 49.05     %D(3): 48.93

RSI:

RSI(14): 57.75

52-Week:

High: 15.8  Low: 2.69  Change(%): 331.3

Average Vol(K):

3-Month: 60618  10-Days 59030

Strong Sell ★★ Sell ★★★ Neutral ★★★★ Buy ★★★★★ Strong Buy

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
DRNA has closed above bottom band by 48.1%. Bollinger Bands are 34.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

2018-05-17T17:35:12-04:00
After Hours Gainers / Losers (05/17/2018)

2018-05-14T21:00:50-04:00
Dicerna Pharmaceuticals' (DRNA) CEO Douglas Fambrough on Q1 2018 Results - Earnings Call Transcript

2018-05-14T16:47:31-04:00
Dicerna Pharmaceuticals beats by $0.08, misses on revenue

2018-05-14T16:10:49-04:00
Dicerna Pharmaceuticals beats by $0.08, misses on revenue

2018-05-14T16:05:00-04:00
Dicerna Reports First Quarter 2018 Financial and Operating Results and Provides Corporate Update

2018-05-10T02:04:51-04:00
Institutional Top Ideas Series: Ra Capital Management

2018-05-07T07:30:00-04:00
Dicerna to Report First Quarter 2018 Financial Results and Host Conference Call on May 14, 2018

2018-05-03T09:55:05-04:00
Eidos Therapeutics commences mid-stage study of lead drug in ATTR

Financial Analysis

Growth

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.

Profitability

Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.

Solvency

Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.

Efficiency

Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.

Click here to get more fundamental analysis.

 

Free Technical Analysis Charts

Stock Basics & Statistics

Sector:  Healthcare

Industry:  Bio Therapeutic Drugs

Shares Out. (M)

51.80

Shares Float (M)

51.54

% Held by Insiders

0.50

% Held by Institutions

79.00

Shares Short (K)

1340

Shares Short Prior Month (K)

380

Stock Financials

EPS

-3.650

EPS Est. Current Year

-2.700

EPS Est. Next Year

-2.760

EPS Est. Next Quarter

-0.690

Forward EPS

-1.640

Book Value (p.s.)

7.190

PEG Ratio

Profit Margin

Operating Margin

-2660.83

Return on Assets (ttm)

-93.1

Return on Equity (ttm)

-112.5

Qtrly Rev. Growth

966.2

Gross Profit (p.s.)

Sales Per Share

EBITDA (p.s.)

-0.854

Qtrly Earnings Growth

Operating Cash Flow (M)

-45.33

Levered Free Cash Flow (M)

-25.78

atoplab.com

Valuation

P/E

-3.82

P/E Growth Ratio

0.01

P/BV

1.94

P/S

7215739904.00

P/CF

-15.92

Dividend Yield

Dividends & Splits

Dividend

Dividend Pay Date

Invalid DateTime.

Ex-Dividend Date

Invalid DateTime.

Forward Dividend

Last Split Date

Last Split Ratio

-1e+010

 

(c) 2006-2017 Stoxline.com | Contact us | NYSE, NASDAQ, AMEX Stock symbols

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.